Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company pioneering targeted cancer therapies through its proprietary Phospholipid Drug Conjugate™ platform. This centralized news resource provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access real-time information about CLRB’s radiopharmaceutical pipeline, including lead candidate iopofosine I 131 for hematologic malignancies and emerging programs targeting solid tumors. Our news collection covers critical updates ranging from trial results to manufacturing advancements, all curated to support informed decision-making.
Key content areas include clinical trial progress, FDA designations, scientific presentations, and corporate collaborations. The platform serves as a reliable source for tracking the company’s mission to improve cancer treatment precision through its novel drug delivery technology.
Bookmark this page for continuous access to verified updates about Cellectar’s innovative oncology programs. Check regularly for new developments in targeted radiopharmaceuticals and PDC platform applications across therapeutic areas.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported financial results for the year ended December 31, 2022, highlighting a net loss of $28.6 million, or $4.05 per share, compared to a net loss of $24.1 million, or $4.35 per share, in 2021. The company held cash and equivalents of $19.9 million, down from $35.7 million in 2021, with a net cash usage of approximately $25.2 million. R&D expenses rose to $19.2 million from $17.6 million, while G&A expenses increased to $9.5 million from $6.5 million. Notably, the company presented positive clinical data from ongoing trials and announced key leadership appointments, strengthening its commercial strategy in hematology and oncology.
On March 8, 2023, Cellectar Biosciences (NASDAQ: CLRB) announced its participation in two upcoming investor conferences. The Roth Capital Partners 35th Annual Conference will take place on March 13, 2023, featuring a fireside chat from 8:30 to 8:55 AM ET. The Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 14, 2023, with a virtual presentation from 10:00 to 10:30 AM ET. Both events will include opportunities for one-on-one meetings with investors. Cellectar's focus is on developing cancer-targeting drugs, including its lead product, iopofosine, undergoing pivotal studies for various cancers.
Cellectar Biosciences (NASDAQ: CLRB) announced that a 61-year-old female patient with primary central nervous system lymphoma (PCNSL) achieved a complete response in the Phase 2 CLOVER-1 Trial. The patient, previously treated with four lines of therapy, showed a 93% tumor volume reduction after two cycles of iopofosine I 131. CT scans confirmed total tumor resolution by day 92. This breakthrough is significant, as there are currently no approved treatments for CNS lymphoma, which typically has poor prognosis (5-year survival of 30%). Cellectar continues to explore the efficacy of iopofosine in other hematological malignancies and pediatric cancers.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has appointed Andrei Shustov, M.D., as Senior Vice President, Medical. He will oversee the clinical development program and medical affairs, reporting directly to CEO James Caruso. Dr. Shustov brings over 30 years of hematology experience, previously serving at Seagen, Inc., and as a full professor at the University of Washington. His expertise aims to advance the company's iopofosine I 131 treatment, targeting Waldenström’s macroglobulinemia. Cellectar has also granted him 100,000 stock options as an inducement for his employment, subject to board approval. The company focuses on cancer drug development, leveraging its Phospholipid Drug Conjugate™ technology.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced the appointment of Shane Lea as chief commercial officer on November 21, 2022. Mr. Lea has extensive experience in hematology and oncology, previously holding senior positions at TG Therapeutics and Celgene-BMS. His expertise is expected to enhance Cellectar's commercial strategy as they prepare for the approval of iopofosine, a targeted therapy for Waldenstrom’s macroglobulinemia. The company granted him a stock option of 100,000 shares as part of his inducement package in accordance with Nasdaq rules.
Cellectar Biosciences (NASDAQ: CLRB) has successfully resolved a lawsuit regarding employee contracts and intellectual property rights related to cancer treatment. The company secured an irrevocable, non-exclusive license to the patents involved. This resolution allows Cellectar to maintain exclusivity over its cancer-targeting PLE technology platform, including iopofosine. The company continues its clinical trials for iopofosine, targeting patients with relapsed or refractory cancers, while also expanding its intellectual property rights to enhance its drug development efforts.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) reported its financial results for Q3 2022, highlighting a net loss of $7.8 million, or $1.28 per share, compared to a loss of $5.8 million in Q3 2021. The company raised $10.7 million through direct and private placements, with plans to utilize funds for clinical studies and general corporate expenses. Notable developments include a 50% overall response rate in a Phase 2 study for multiple myeloma and a $2 million grant from the NCI to expand pediatric trials. Cash and equivalents totaled $17.8 million as of September 30, 2022, down from $35.7 million at year-end 2021.
